1. Thomas ED. Marrow transplantation for malignant diseases.J Clin Oncol. 1983;1:517–531.
2. Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation: Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.Lancet. 1998;352:1087–1092.
3. Passweg JR, Rowlings PA, Armitage JO, et al. Report from the International Bone Marrow Transplant Registry and Autologous Blood and Marrow Transplant Registry: North America. In: Cecka JM, Teraskaki PI, eds.Clinical Transplants, 1995. Los Angeles, Calif: UCLA Tissue Typing Laboratory; 1996:117–127.
4. Bast CR. Principles of cancer biology: tumour immunology. In: DeVitta VT, Hellman S, Rosenberg SA, eds.Cancer: Principles and Practice of Oncology. Philadelphia, Pa: J. B. Lippincott; 1985:125–141.
5. Weiss L, Lubin I, Factorowich Y, et al. Effective graft-versus- leukemia effects independent of graft-versus-host disease after T-cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma: role of cell therapy and recombinant IL-2.J Immunol. 1994;153:2562–2567.